Gepant treAtments: EffectIveNess and tolERability (GAINER) - Trial NCT05903027
Access comprehensive clinical trial information for NCT05903027 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Florence and is currently Not yet recruiting. The study focuses on Migraine,Migraine With Aura,Migraine Without Aura,Chronic Migraine. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Rimegepant 75 MG Disintegrating Oral Tablet
Observational
drug
Sponsor & Location
University of Florence
Timeline & Enrollment
N/A
Jun 01, 2023
Jun 01, 2024
Primary Outcome
Headache pain freedom at 2 hours post-dose during the first attack,Occurrence of treatment-emergent adverse events
Summary
The purpose of this prospective and multicentric study is to evaluate the effectiveness and
 tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic
 migraine patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05903027
Non-Device Trial